Parameter HPLC TLC D1 DD1 Reportede method Mean ± %RSDa (Xarelto)b 98.44 ± 0.3 101.87 ± 0.1 99.71 ± 1.7 101.52 ± 0.1 99.08 ± 1.1 Variance 0.6 1.6 1.8 1.4 1.1 n 5 5 5 5 5 t-test (2.30)c 0.11 0.10 0.82 0.15 - F-ratio (6.39)c 1.85 1.45 1.63 1.23 - %Recoveryd 100.8 ± 1.1 99.7 ± 0.3 100.20 ± 0.5 99.74 ± 1.1 - aPercentage relative standard deviation for five determinations. bLabeled to contain 10 mg per tablet. cTheoretical value for t and F for P=0.05. dStandard addition of different concentrations of rivaroxaban. eReported HPLC method using C18(4.6×10 cm 5 μm) column, mobile phase acetonitrile and water pH 3(30:70), flow rate 1.2 ml min-1 and detection at 250 nm. The retension time of rivaroxaban was at 2.5 min (not stability indicating method).

Table 4: Determination of rivaroxaban in pharmaceutical formulation by the proposed methods.